Asia Study Group of Prostate Cancer (A-CaP Study)

Japan Study Group of Prostate Cancer

Status: Invitation-only

Conditions: Prostate Cancer

Study type: Observational

Funder types: Other

Identifiers

NCT02873013

A-CaP2015-2026

Details and patient eligibility

About

This study will target patients who have received a histopathological diagnosis of prostate cancer and who are undergoing treatment in various forms, including active PSA surveillance, surgical treatment, radiotherapy, endocrine therapy, and chemotherapy. The study will survey information about the patient at time of diagnosis, clinical staging, details of initial treatment, status of disease progression, and prognosis at the end point of the study. The purpose of the study is to clarify distribution of staging, the actual status of treatment choices and treatment outcomes.

Full description

The A-CaP will collect information in a linkable anonymized format from all medical institutions in Asian countries participating in the study and will engage in data analysis. J-CaP which has previous experience of engaging in a similar study in 2010 wll be a sponsor for A-CaP study, the aggregated results of which have been reported. The registration period for this study will be three years followed by 7 years of follow-up study, and research will be implemented across a wider range of Asian countries, with new institutions participating for the purposes of this study. As this study will be an observational study the acquisition of data will be relatively simple, and as the content of the study will be almost identical to the study conducted by J-CaP in 2010, a system for research implementation is already established at J-CaP.

Enrollment: 20,000 estimated patients

Sex: Male

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients who have received a histopathological diagnosis of prostate cancer between January 1,2016,and December 31,2018.
• Patients who, having received a diagnosis within the abovementioned period, began initial treatment for prostate cancer(including active surveillance).
• Patients who are either hospitalized as outpatients.

Exclusion criteria

• Patients for whom information about the time of diagnosis, including histopathological diagnosis, cannot be acquired.

Trial design

20,000 participants in 1 patient group

Prostate Cancer

Description:

About 20,000 patients who have received a histopathological diagnosis of prostate cancer from ten countries in Asia.